ArticleThe journal of nutrition, health & aging2026
Association of growth differentiation factor-15 with muscle wasting and anemia in chronic kidney disease.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitokines as bioenergetic stress signals in cardiovascular disease: mitochondrial communication, endocrine adaptation, and translational implications.Journal of bioenergetics and biomembranes · 2026Review
- GDF15 in aging, metabolic disease and cachexia.The journal of nutrition, health & aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCachexia, characterized by muscle wasting and anemia, is a major complication of chronic kidney disease (CKD). Growth differentiation factor-15 (GDF-15), a stress-responsive cytokine implicated in cancer cachexia, is markedly elevated in CKD and linked to disease progression. However, the role of GDF-15 in CKD-related cachexia remains unclear.
methodsWe conducted a cross-sectional study of 268 patients with stage 3-5 CKD not yet on dialysis. Plasma GDF-15 concentrations were measured using immunoassays. Lean body mass was assessed by multifrequency bioimpedance spectroscopy with the Body Composition Monitor (BCM), and appendicular skeletal muscle mass (ASM) was estimated using a validated BCM-derived equation. Muscle wasting was defined as ASM index <7.0 kg/m² in men or <5.7 kg/m² in women, according to Asian Working Group for Sarcopenia criteria. Anemia was defined as hemoglobin <13 g/dL in men or <12 g/dL in women, based on KDIGO criteria. Associations of GDF-15 with muscle wasting and anemia, two core features of CKD cachexia, were examined using multivariable regression models. MAIN
findingsMedian plasma GDF-15 concentration was 2674 (range 550-12466) pg/mL. Higher GDF-15 was independently associated with lower lean tissue index and lower hemoglobin (both P < 0.001). Additional independent determinants of GDF-15 included age, male sex, diabetes, smoking status, eGFR, proteinuria, ferritin, and NT-proBNP. In multivariable logistic regression, each natural log increase in GDF-15 was associated with greater odds of both muscle wasting (OR 2.93, 95% CI 1.23-6.97, P = 0.015) and anemia (OR 3.45, 95% CI 1.09-10.91, P = 0.035).
conclusionElevated GDF-15 is associated with muscle wasting and anemia in CKD independent of age, sex, comorbidities, and kidney function, mirroring its role in cancer cachexia. These findings suggest that GDF-15 may reflect pathophysiological processes linked to cachexia-related phenotypes and warrants further investigation as a potential therapeutic target in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.